Ten patients with metastatic disease to the liver were treated with difluoromethylornithine (DFMO) administered by continuous hepatic arterial infusion. Two of nine evaluable patients had an objective partial response. Stable disease was recorded in three patients. Ototoxicity was encountered in all patients who received a daily dose of DFMO equal to or greater than 1.0 g/m2.
|Original language||English (US)|
|Number of pages||5|
|State||Published - Feb 1 1989|
All Science Journal Classification (ASJC) codes
- Cancer Research